Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $170.00 short call and a strike $180.00 long call offers a potential 6.95% return on risk over the next 12 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $170.00 by expiration. The full premium credit of $0.65 would be kept by the premium seller. The risk of $9.35 would be incurred if the stock rose above the $180.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 55.19 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Valeant: The Milken Meteor Strikes Allergan
Mon, 09 Jun 2014 20:43:00 GMT
Ackman explains Valeant bid
Mon, 09 Jun 2014 11:52:00 GMT
Ackman says Allergan holders back takeover at $180/shr-CNBC
Mon, 09 Jun 2014 11:33:38 GMT
Reuters – Activist investor William Ackman on Monday defended Valeant Pharmaceuticals during an interview on CNBC television and said that Allergan Inc shareholders told him they would support a deal at $180 per share. Ackman, who said that Valeant was a company in the model of esteemed investor Warren Buffett's Berkshire Hathaway Inc rather than Tyco Inc, said that he met with Allergan's large shareholders before Valeant raised its bid to about that level on May 30. Ackman, who owns almost 10 percent of Allergan, and Valeant are in the midst of a hostile takeover battle.
Pharma industry ‘Shakespearean drama'
Mon, 09 Jun 2014 11:19:00 GMT
CNBC – Discussing the evolution of big pharmaceutical companies, and Valeant's old and new R&D model, with Michael Porter, Harvard Business School professor. Bill Ackman, founder and CEO of Pershing Square Capital …
Ackman says Chanos wrong on Valeant
Mon, 09 Jun 2014 11:09:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook